Amylyx Pharmaceuticals

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$0
$0
$-665
$416
Gross Profit
-141
0
-825
-393
EBITDA
-41,302
-37,647
-40,494
-75,440
EBIT
-41,443
-37,803
-40,654
-75,661
Net Income
-41,443
-35,907
-37,546
-72,704
Net Change In Cash
0
0
-665
416
Free Cash Flow
-25,265
-39,835
-59,028
-41,551
Cash
58,085
59,764
77,391
71,839
Basic Shares
89,138
85,697
68,593
68,091

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$87,371
$380,786
$22,230
$285
Gross Profit
-37,262
355,345
19,237
285
EBITDA
-290,976
39,890
-200,854
-82,636
EBIT
-291,880
38,802
-201,341
-82,688
Net Income
-301,743
49,271
-198,375
-87,879
Net Change In Cash
87,371
380,786
22,230
285
Cost of Revenue
12,930
Free Cash Flow
-167,804
10,678
-182,397
-75,152
Cash
77,391
170,201
62,526
50,191
Basic Shares
68,142
69,991
66,512
57,864

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
-$0.46
2025-03-31
-$0.42
2024-12-31
-$0.55